Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-12-08 English
1st Patient Dosed in ProstACT Global Randomized Tx Expansion 3 pages 220.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated December 8, 2025, providing an update on the ProstACT Global Phase 3 clinical trial, specifically the dosing of the first patient in Part 2 of the study and plans for data readout. It discusses clinical trial progress, regulatory interactions with FDA and EMA, and expansion plans. The document is a corporate announcement about clinical trial progress and regulatory engagement, not a financial report, earnings release, or detailed investor presentation. It does not contain financial statements, management discussion of financial results, or detailed governance or capital structure information. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The content fits best into a general regulatory announcement category as it informs the market about clinical trial progress and regulatory plans without fitting into more specific financial or governance categories.
2025-12-07 English
Becoming a substantial holder 62 pages 3.9MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act 2001 Section 671B, which pertains to the notice of an initial substantial holder. The content details the substantial shareholding of JPMorgan Chase & Co. and its affiliates in Telix Pharmaceuticals Ltd, including voting power, relevant interests, registered holders, consideration paid, and associated entities. The document is a regulatory filing notifying the market and regulators about a significant shareholding position crossing a threshold. It is not a financial report, earnings release, or management discussion. It is a formal notification of a major shareholding change, which aligns with the category 'Major Shareholding Notification' (Code: MRQ). The document length and detail confirm it is the actual notification, not just an announcement of a report. Therefore, the correct classification is MRQ with high confidence.
2025-11-16 English
Application for quotation of securities - TLX 8 pages 25.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the issuance and conversion of options and other convertible securities into ordinary fully paid shares, including specifics about the number of securities, issue dates, prices, and whether the securities are held by key management personnel. The document is a regulatory announcement about new securities being quoted, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the securities issued. This type of document fits the category of Share Issue/Capital Change (SHA), as it announces new share issues and capital changes.
2025-11-06 English
Appendix 3Y Change in Director Interests - C Behrenbruch 3 pages 342.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities holdings of a company director, including the number of shares and options held before and after the change, the nature of the change (exercise of options), and the value of the transaction. This type of document is a formal notification of personal share transactions by a company director. It is not a financial report, earnings release, or management discussion, but specifically a report of insider trades by directors. Therefore, it fits the category 'Director's Dealing' (DIRS). The document length and content confirm it is the actual notice, not just an announcement or certification.
2025-11-06 English
Application for quotation of securities - TLX 6 pages 20.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new ordinary shares following a contractual milestone event. The document includes specifics about the number of securities, issue date, consideration, and compliance with listing rules. It is not a financial report, earnings release, or management discussion, but rather an announcement related to capital changes and securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement or a report publication notice but a formal application for quotation of securities.
2025-10-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.